17.00
price up icon3.34%   0.55
after-market After Hours: 17.00
loading
Novocure Ltd stock is traded at $17.00, with a volume of 2.84M. It is up +3.34% in the last 24 hours and up +4.10% over the past month. NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
See More
Previous Close:
$16.45
Open:
$16.63
24h Volume:
2.84M
Relative Volume:
2.88
Market Cap:
$2.13B
Revenue:
$577.74M
Net Income/Loss:
$-149.78M
P/E Ratio:
-12.14
EPS:
-1.4
Net Cash Flow:
$-78.21M
1W Performance:
-11.04%
1M Performance:
+4.10%
6M Performance:
-39.20%
1Y Performance:
-23.25%
1-Day Range:
Value
$16.55
$17.32
1-Week Range:
Value
$16.22
$19.11
52-Week Range:
Value
$14.17
$34.13

Novocure Ltd Stock (NVCR) Company Profile

Name
Name
Novocure Ltd
Name
Phone
44 (0)15 3475 6700
Name
Address
NO. 4 THE FORUM, ST. HELIER
Name
Employee
1,488
Name
Twitter
@novocure
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
NVCR's Discussions on Twitter

Compare NVCR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Medical Devices icon
NVCR
Novocure Ltd
17.00 2.13B 577.74M -149.78M -78.21M -1.40
Medical Devices icon
ABT
Abbott Laboratories
133.58 232.41B 42.34B 13.50B 6.66B 7.71
Medical Devices icon
BSX
Boston Scientific Corp
102.09 155.73B 17.55B 2.03B 2.72B 1.37
Medical Devices icon
SYK
Stryker Corp
383.89 146.23B 23.22B 2.86B 3.58B 7.40
Medical Devices icon
MDT
Medtronic Plc
87.44 106.37B 33.54B 4.66B 5.19B 3.62
Medical Devices icon
EW
Edwards Lifesciences Corp
77.52 45.88B 5.54B 4.18B 623.10M 7.00

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-02-24 Upgrade Evercore ISI In-line → Outperform
Oct-16-24 Upgrade H.C. Wainwright Neutral → Buy
Nov-20-23 Resumed JP Morgan Neutral
Aug-28-23 Downgrade H.C. Wainwright Buy → Neutral
Aug-08-23 Upgrade Piper Sandler Neutral → Overweight
Aug-04-23 Initiated SVB Securities Outperform
Jul-31-23 Upgrade Evercore ISI Underperform → In-line
Jun-07-23 Upgrade Wedbush Underperform → Neutral
May-16-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-17-23 Downgrade JP Morgan Neutral → Underweight
Jan-06-23 Downgrade Wells Fargo Overweight → Equal Weight
Jan-05-23 Reiterated H.C. Wainwright Buy
Nov-29-22 Upgrade Wells Fargo Equal Weight → Overweight
Oct-24-22 Downgrade Piper Sandler Overweight → Neutral
Jul-05-22 Downgrade Evercore ISI In-line → Underperform
May-16-22 Initiated H.C. Wainwright Buy
Feb-08-22 Initiated Loop Capital Buy
Feb-02-22 Upgrade Oppenheimer Perform → Outperform
Jan-20-22 Upgrade Truist Hold → Buy
Jan-03-22 Upgrade Evercore ISI Underperform → In-line
Jul-01-21 Downgrade Mizuho Buy → Neutral
Apr-14-21 Downgrade Wedbush Neutral → Underperform
Jan-25-21 Reiterated Piper Sandler Overweight
Sep-23-20 Initiated Northland Capital Outperform
Sep-18-20 Downgrade Wells Fargo Overweight → Equal Weight
Sep-17-20 Downgrade Truist Buy → Hold
Jun-01-20 Resumed Oppenheimer Perform
May-01-20 Downgrade Oppenheimer Outperform → Perform
Apr-09-20 Downgrade Evercore ISI In-line → Underperform
Mar-05-20 Upgrade Wells Fargo Equal Weight → Overweight
Jan-02-20 Downgrade Evercore ISI Outperform → In-line
Jul-29-19 Upgrade SunTrust Hold → Buy
Jul-26-19 Downgrade JP Morgan Overweight → Neutral
Jul-26-19 Downgrade Wedbush Outperform → Neutral
Mar-20-19 Initiated SunTrust Hold
Nov-02-18 Downgrade Wells Fargo Outperform → Market Perform
Jul-16-18 Initiated Evercore ISI Outperform
Apr-18-18 Reiterated Mizuho Buy
Feb-23-18 Reiterated Mizuho Buy
May-24-17 Upgrade Wells Fargo Market Perform → Outperform
Jul-29-16 Reiterated Wedbush Outperform
Jan-19-16 Initiated Barclays Underweight
Dec-02-15 Initiated Deutsche Bank Hold
View All

Novocure Ltd Stock (NVCR) Latest News

pulisher
Jun 06, 2025

NovoCure Ltd (NVCR) Shares Up 4.08% on Jun 6 - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial - TradingView

Jun 06, 2025
pulisher
Jun 06, 2025

Mackenzie Financial Corp Purchases Shares of 6,820 NovoCure Limited (NASDAQ:NVCR) - Defense World

Jun 06, 2025
pulisher
Jun 04, 2025

Novocure at Jefferies Conference: Expanding Horizons in Cancer Treatment - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

Insider Sell Alert: Frank Leonard Sells 30,196 Shares of NovoCure Ltd (NVCR) - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Ameriprise Financial Inc. Has $682,000 Position in NovoCure Limited (NASDAQ:NVCR) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

H.C. Wainwright reiterates Buy rating on NovoCure stock after ASCO data - Investing.com Nigeria

Jun 02, 2025
pulisher
Jun 02, 2025

NovoCure Ltd (NVCR) Shares Down 7.43% on Jun 2 - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

Novocure (NVCR) Gains Support for Future Launch from Promising Trial Outcomes | NVCR Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 01, 2025

Novocure (NVCR) Announces Positive Phase 3 Trial Results for Pancreatic Cancer Therapy | NVCR Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Novocure announces results from Phase 3 PANOVA-3 trial - TipRanks

Jun 01, 2025
pulisher
May 31, 2025

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 - GuruFocus

May 31, 2025
pulisher
May 31, 2025

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Lelezard

May 31, 2025
pulisher
May 31, 2025

Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting | NVCR Stock News - GuruFocus

May 31, 2025
pulisher
May 31, 2025

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Yahoo Finance

May 31, 2025
pulisher
May 30, 2025

NovoCure Ltd (NVCR) Shares Gap Down to $18.5801 on May 30 - GuruFocus

May 30, 2025
pulisher
May 28, 2025

Nuveen Asset Management LLC Lowers Position in NovoCure Limited (NASDAQ:NVCR) - Defense World

May 28, 2025
pulisher
May 27, 2025

Novocure Announces Upcoming Investor Events | NVCR Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Novocure Announces Upcoming Investor Events - Yahoo Finance

May 27, 2025
pulisher
May 22, 2025

Is NovoCure (NASDAQ:NVCR) Using Debt Sensibly? - simplywall.st

May 22, 2025
pulisher
May 22, 2025

BNP Paribas Financial Markets Sells 147,371 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World

May 22, 2025
pulisher
May 17, 2025

Dimensional Fund Advisors LP Sells 3,016 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World

May 17, 2025
pulisher
May 15, 2025

Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect? - Yahoo Finance

May 15, 2025
pulisher
May 12, 2025

Tower Research Capital LLC TRC Sells 6,669 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World

May 12, 2025
pulisher
May 11, 2025

Raymond James Financial Inc. Purchases Shares of 11,672 NovoCure Limited (NASDAQ:NVCR) - Defense World

May 11, 2025
pulisher
May 10, 2025

Investor Network: Novocure Ltd. to Host Earnings Call - ACCESS Newswire

May 10, 2025
pulisher
May 10, 2025

NovoCure Limited (NASDAQ:NVCR) Given Average Rating of “Moderate Buy” by Analysts - Defense World

May 10, 2025
pulisher
May 09, 2025

NovoCure Ltd (NVCR)’s Market Momentum: Closing Strong at 20.62, Down -3.28 - DWinneX

May 09, 2025
pulisher
May 07, 2025

Envestnet Asset Management Inc. Buys New Holdings in NovoCure Limited (NASDAQ:NVCR) - Defense World

May 07, 2025
pulisher
May 07, 2025

Mariner LLC Acquires Shares of 8,631 NovoCure Limited (NASDAQ:NVCR) - Defense World

May 07, 2025
pulisher
May 06, 2025

Comparing Meihua International Medical Technologies (NASDAQ:MHUA) & NovoCure (NASDAQ:NVCR) - Defense World

May 06, 2025
pulisher
May 02, 2025

Ratio Analysis: Unpacking NovoCure Ltd (NVCR)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX

May 02, 2025
pulisher
May 02, 2025

A year in review: NovoCure Ltd (NVCR)’s performance in the last year - uspostnews.com

May 02, 2025
pulisher
Apr 29, 2025

Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High? - Yahoo Finance

Apr 29, 2025
pulisher
Apr 29, 2025

NovoCure Ltd’s latest rating changes from various analysts - knoxdaily.com

Apr 29, 2025
pulisher
Apr 28, 2025

What is NovoCure Ltd (NVCR) Stock Return on Shareholders’ Capital? - Sete News

Apr 28, 2025
pulisher
Apr 28, 2025

Russell Investments Group Ltd. Sells 2,135 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World

Apr 28, 2025
pulisher
Apr 26, 2025

NovoCure First Quarter 2025 Earnings: Beats Expectations - simplywall.st

Apr 26, 2025
pulisher
Apr 25, 2025

H.C. Wainwright maintains Buy on NovoCure, $38 price target By Investing.com - Investing.com Canada

Apr 25, 2025
pulisher
Apr 25, 2025

NovoCure Ltd [NVCR] Shares Jump Approximately 56.80% Over the Year - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

Why NovoCure Stock Skyrocketed This Week - Yahoo Finance

Apr 25, 2025
pulisher
Apr 25, 2025

H.C. Wainwright maintains Buy on NovoCure, $38 price target - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

NovoCure Limited (NASDAQ:NVCR) Q1 2025 Earnings Call Transcript - Insider Monkey

Apr 25, 2025
pulisher
Apr 25, 2025

NovoCure (NASDAQ:NVCR) Cut to “Sell” at StockNews.com - Defense World

Apr 25, 2025
pulisher
Apr 25, 2025

NovoCure (NASDAQ:NVCR) Shares Gap Up After Earnings Beat - Defense World

Apr 25, 2025
pulisher
Apr 25, 2025

NovoCure: Q1 Earnings Snapshot - Huron Daily Tribune

Apr 25, 2025
pulisher
Apr 25, 2025

Bank of Montreal Can Buys New Position in NovoCure Limited (NASDAQ:NVCR) - Defense World

Apr 25, 2025
pulisher
Apr 25, 2025

Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Novocure’s Q1 2025: Revenue Growth and Strategic Advances - TipRanks

Apr 25, 2025

Novocure Ltd Stock (NVCR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
medical_devices PHG
$23.46
price up icon 0.56%
$311.77
price down icon 1.70%
medical_devices STE
$243.72
price up icon 0.06%
$71.62
price up icon 0.10%
$86.67
price up icon 1.08%
medical_devices EW
$77.52
price down icon 0.32%
Cap:     |  Volume (24h):